TABLE 1.
Percentages of subjects achieving meningococcal serogroup C rSBA titers ≥8 or ≥128 and rSBA GMTs before and 1, 2, 12, and 24 months following administration of Menitorix at 12 to 14 months of age, by priming MCC vaccine
| Time from administration of Menitorix (mo) | Parameter | Result obtained with the following priming meningococcal serogroup C conjugate vaccine: |
||
|---|---|---|---|---|
| Meningitec | Menjugate | NeisVac-C | ||
| Preboosting | No. of subjects | 71 | 66 | 65 |
| GMT (95% CI) | 3.3 (2.5-4.3) | 3.7 (2.7-5.0) | 8.7 (5.7-13.3) | |
| % of subjects with a titer ≥8 (95% CI) | 17 (9-28) | 21 (12-33) | 48 (35-60) | |
| % of subjects with a titer ≥128 (95% CI) | 6 (2-14) | 5 (1-13) | 14 (7-25) | |
| 1 | No. of subjects | 80 | 91 | 76 |
| GMT (95% CI) | 368.4 (253.7-534.9) | 467.3 (329.8-662.1) | 2,085.7 (1,475.6-2,948.0) | |
| % of subjects with a titer ≥8 (95% CI) | 95 (88-99) | 96 (89-99) | 100 (95-100) | |
| % of subjects with a titer ≥128 (95 % CI) | 86 (77-93) | 88 (79-94) | 97 (91-100) | |
| 2 | No. of subjects | 36 | 45 | 43 |
| GMT (95% CI) | 128.0 (69.4-235.9) | 343.0 (203.8-577.3) | 1,413.6 (882.7-2,263.8) | |
| % of subjects with a titer ≥8 (95% CI) | 89 (74-97) | 96 (85-99) | 100 (92-100) | |
| % of subjects with a titer ≥128 (95% CI) | 64 (46-79) | 82 (68-92) | 98 (88-100) | |
| 12 | No. of subjects | 63 | 84 | 66 |
| GMT (95% CI) | 6.5 (4.2-10.1) | 7.0 (4.9-10.0) | 82.3 (48.5-139.9) | |
| % ≥8 (95% CI) | 33 (22-46) | 38 (28-49) | 85 (74-92) | |
| % ≥128 (95% CI) | 11 (5-22) | 10 (4-18) | 55 (42-67) | |
| 24 | No. of subjects | 35 | 45 | 42 |
| GMT (95% CI) | 3.6 (2.4-5.6) | 4.3 (2.8-6.7) | 9.0 (5.0-16.0) | |
| % of subjects with a titer ≥8 (95% CI) | 23 (10-40) | 22 (11-37) | 43 (28-59) | |
| % of subjects with a titer ≥128 (95% CI) | 3 (0-15) | 9 (2-21) | 19 (9-34) | |